Business Wire

IL-ISACA

26.1.2021 17:18:12 CET | Business Wire | Press release

Share
ISACA Releases New Report on Privacy Trends, Obstacles and Predictions Ahead of Data Privacy Day

As Data Privacy Day approaches this week, ISACA has released a new survey report, Privacy in Practice 2021: Data Privacy Trends, Forecasts and Challenges , exploring past and future trends in privacy by design, privacy obstacles and privacy workforce.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005846/en/

Privacy by Design

Enterprises that report they always use privacy by design are more likely to be driven by a combination of compliance and ethics (62 percent vs. 52 percent total). They are also nearly two-and-a-half times more likely to be completely confident in their privacy team’s ability to ensure data privacy and achieve compliance with new privacy laws and regulations (24 percent vs. 10 percent total). However, there was not a meaningful difference in the number of privacy breaches they experienced in the last 12 months compared to all respondents. Approximately 10 percent of both groups reported breaches—a potentially underreported number.

Privacy Obstacles

Respondents identified other common privacy failures, including:

  • Lack of training or poor training (64 percent)
  • Failure to perform a risk analysis (53 percent)
  • Bad or nonexistent detection of personal information (50 percent)

Respondents cited privacy principles frameworks, experience-based credentials and privacy training as the most helpful methods in overcoming these obstacles.

Workforce Trends

Respondents indicated that they foresee an increased demand for technical privacy roles compared to legal/compliance roles (70 percent increase vs. 59 percent increase). However, technical privacy roles were more likely to be considered understaffed (46 percent vs. 33 percent).

Nevertheless, hiring managers have been filling these roles through training—47 percent noted they have been training non-privacy staff interested in moving into privacy roles. Ninety-two percent of respondents indicated that they have privacy staff who started their career in IT or security and moved into privacy and compliance.

“Organizations will continue needing a strong privacy workforce in the years ahead,” says Nader Qaimari, ISACA chief product officer. “As non-privacy professionals increasingly get opportunities to train for this career path and gain technical skills, it not only eases the privacy skills gap but enriches this workforce.”

The complimentary webinar, “Exploring Privacy Trends, Challenges & Predictions,” on 28 January 2021 at 12:00 PM EST / 5:00 PM (UTC) will explore the survey highlights. To learn more, visit www.isaca.org/education/online-events/lms_w012821 .

Access the Privacy in Practice 2021 survey report at www.isaca.org/privacy-in-practice-2021 . Learn more about ISACA’s privacy resources, including the Certified Data Privacy Solutions Engineer™ (CDPSE™) certification, at www.isaca.org/cdpse .

About ISACA

For more than 50 years, ISACA® (www.isaca.org ) has equipped individuals with knowledge, credentials, education and community to progress their careers and transform their organizations, and enables enterprises to train and build quality teams. ISACA leverages the expertise of more than 150,000 members who work in information security, governance, assurance, risk and privacy to drive innovation through technology. Its presence in 188 countries includes more than 220 chapters.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye